Skip to content

Photo with eleven men and women, with the label "TAG History"
1/4/6x24: A Campaign to Rally Energy, Political Will, and Funding to End TB
Report cover that reads" Pipeline Report 2023. Pipeline report is white text, and 2023 is gray. The main cover is black with a graphic of blue wavy lines

Pipeline Reports

The current ones are all online and available for download now.

July 18, 2024
2024 Pipeline Report
Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).

July 17, 2024
2023 Annual Report
We’re pleased to share with you our latest Annual Report, which highlights everything we accomplished in 2023.

July 16, 2024
Research Toward a Cure Trials
A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).

July 2, 2024
Administrative Coordinator
Treatment Action Group (TAG) seeks a highly motivated and organized Administrative Coordinator to support the organization as it continues to grow. This position reports to TAG’s Director of Operations and Human Resources. This is a full-time, salaried position.

June 26, 2024
Call For New Global TB CAB Members
On behalf of the Global Tuberculosis Community Advisory Board (TB CAB), we’re excited to announce a call for new member applications.

June 26, 2024
TAG Calls on Danaher to Drop the Prices of GeneXpert Tests and Make the Cost Audit Public
Statement / Press
Treatment Action Group (TAG) calls on Danaher to lower the price of GeneXpert tests for tuberculosis (TB) and other diseases to $5 each in accordance with publicly available evidence of the cost of manufacturing and to commit to public transparency of the cost audit of Xpert MTB/RIF Ultra.

June 20, 2024
An Open Letter to Médecins Sans Frontières — Urgent Call to Reverse the Devastating Decision to Shutter the MSF Access Campaign
Letter / Comment
TAG’s emergency plea to our allies at MSF to preserve its life-saving and world-changing MSF Access Campaign (Campaign for Access to Essential Medicines) — we need them now more than ever!

June 20, 2024
Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions
Statement / Press
Treatment Action Group (TAG) welcomes the news that the long-acting injectable HIV capsid inhibitor lenacapavir has proven efficacious at preventing HIV acquisition among young women and adolescent girls in South Africa and Uganda.

June 11, 2024
Frequently Asked Questions on Microarray Patches (MAPs)
Microarray patches (MAPs) are arrays of microneedles that stick to your skin like a bandage, offering a noninvasive mechanism for drug administration.

May 30, 2024
Comments Delivered at the WHO Director-General’s TB Vaccine Accelerator Council
Letter / Comment
These are the remarks delivered by Mike Frick, TAG’s TB co-director, who was speaking as a civil society representative, at the 2nd meeting of the WHO Director-General’s TB Vaccine Accelerator Council in Geneva Switzerland.

May 22, 2024
Treatment Action Group Calls on NY City Council to Override and Mayor Adams to Reverse Egregious Cuts to New York City HIV Funding
Statement / Press
In response to disheartening news of the proposed $5.3 million cut in HIV/AIDS funding by the Adams administration, we at Treatment Action Group (TAG) express our resolute opposition, in solidarity with our partner organizations that would be harmed by the egregious, unconscionable cuts to HIV services and programs in New York City.

May 17, 2024
TAG Comments at UN High-Level Meeting on Antimicrobial Resistance Hearing
Letter / Comment
TAG delivered an intervention at the UN High-Level Meeting on Antimicrobial Resistance (AMR) Multistakeholder Hearing, calling on member states to incorporate drug-resistant TB (DR-TB) in the political declaration as a key component of AMR response.

May 15, 2024
TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing
Webinar / Presentation
On May 15, 2024, TAG hosted this webinar on the TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing.

May 13, 2024
Comments In Regard to NIAID’S Strategic Plan, May 2024
Letter / Comment
Treatment Action Group submitted comments in response to “Request for Information (RFI): Inviting Comments and Suggestions on NIAID’s Strategic Plan” highlighting the organization’s key priorities across the NIAID portfolio.

May 10, 2024
An Activist’s Guide to Rifapentine – TB Preventive Treatment: 3HP and 1 HP
Rifapentine, an off-patent drug that’s been around since the 1960s, is the cornerstone of the two most effective regimens to prevent tuberculosis (TB) in people at risk of the disease.

May 10, 2024
Director of Development
Treatment Action Group (TAG) seeks a dynamic, motivated, and skilled individual to become its Director of Development supporting the organization as it continues to grow.

May 9, 2024
Community Engagement on Microarray Patches
Webinar / Presentation
TAG hosted this May 31 webinar on the growing pipeline of microarray patches (MAPs) for various infectious diseases treatment and immunization.

May 8, 2024
Treatment Action Group Welcomes Two New Board Members
Statement / Press
Treatment Action Group (TAG) is pleased to announce that two new members have been elected to the Board of Directors, Ama Burnham and Dr. Stefan V. Goldberg.

May 7, 2024
Going Behind the Scenes at TAG
Follow along with one of our staff members on a typical day, and you’ll see the difference you make as a TAG donor and partner.

May 7, 2024
Empowering Health, Parts 1 and 2
Webinar / Presentation
On May 7 and 21, TAG celebrated Pride season by hosting for an essential webinar that addressed the unique health concerns of the LGBTQ+ community, focusing on engaging LGBTQ patients.

April 2, 2024
Treatment Action Group Is Organizational Sponsor of SYNChronicity 2024
Statement / Press
Treatment Action Group (TAG) is proud to be one of the organizational sponsors of SYNChronicity 2024 (SYNC 2024). This annual national conference for HIV, HCV, STIs, harm reduction, and LGBTQ health will be held in Arlington, Virginia, from May 29 – 31; more than 1500 attendees are expected to participate.

March 27, 2024
1/4/6×24 Mid-Campaign Report Launch Webinar
Webinar / Presentation
On March 27, 2024, the 1/4/6×24 Campaign and the Stop TB Partnership co-hosted a webinar to launch the Campaign’s new report: Getting Better Faster: Delivering on the Promise of New TB Treatments.

March 22, 2024
Mid-Campaign Report Highlights What’s Needed to Win Better, Shorter TB Treatments for All by End of 2024
Statement / Press
Universal implementation of the best available treatment for drug-susceptible tuberculosis (TB) stands to cut 6.3 million years off total treatment by 2030, a new analysis released today by the 1/4/6×24 Campaign coalition has found.

March 21, 2024
Getting Better Faster: Delivering on the Promise of New TB Treatments – A Report from the 1/4/6×24 Campaign
This report marks the midway point of the 1/4/6×24 Campaign, which calls for the universal implementation of best available TB regimens — as little as one month or once weekly for TB prevention, four months for drug-susceptible TB, and six months for drug-resistant TB — by the end of 2024.

March 18, 2024
Research in Action Awards 2024
Save the Date: Thursday, October 17, 2024, when our Research in Action Awards return this fall! Once again we’ll honor some of the most brilliant activists, scientists, and leaders in the fight to end HIV, tuberculosis (TB), and hepatitis C (HCV).

Back To Top